Prognosis for Dilated Cardiomyopathy Prognosis for dilated cardiomyopathy generally has been poor, although prognosis has improved with current management regimens (eg, use of beta-blockers, angiotensin-converting enzyme [ACE] inhibitors, mineralocorticoid receptor antagonists, sodium glucose cotransporter 2 protein (SGLT2) inhibitors, implantable cardioverter-defibrillators, or cardiac resynchronization therapy).